Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesHot NewsMost Read NewsRecomm.Business LeadersCalendar 

Burzynski Clinic Presents Over Five Years Survival Data From Phase II Trials of ANP for Inoperable Brain Tumors at the Congress

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/16/2013 | 03:34am CEST

The Burzynski Clinic (BC) announced today that it made a keynote speaker presentation at the 2nd Annual Congress of Asia-Pacific Academy of Anti-Aging Medicine in Beijing, China. Based on the presentation in Beijing, a total of 401 eligible patients (patients who received over 28 days of treatment) with advanced inoperable brain tumors have been treated with antineoplaston A10 and antineoplastons AS2-1 therapy (ANP) in phase II studies. Most of the patients (87%) were diagnosed with high-grade tumors and the remaining patients were diagnosed with low-grade tumors. The patients were diagnosed by pathologists not associated with BC and objective responses were verified by Central Radiology Review. The group of 77 patients (19%) survived over five years from the treatment start. Of particular interest were results in patients with brainstem gliomas. The group of 17 patients with brainstem glioma underwent the treatment and 65% of these patients survived over five years. An additional group of 42 patients diagnosed with diffuse intrinsic pontine glioma (DIPG) have been treated and a total of 19% survived over five years.

The quality of survival is very good and there is no long-term toxicity related to ANP.

These clinical results are very encouraging, since they describe a positive ANP effect on some of the worst malignancies in the entire oncology field, but they will require FDA approval.

Burzynski Clinic is committed to developing treatments for cancer based on genomic and epigenomic principles.

Forward-looking statements in this release are made pursuant to the safe harbor provisions of the federal securities laws. Information contained in forward-looking statements is based on current expectations and is subject to change, and future events may differ materially from those discussed herein due to a number of factors, including, but not limited to, risks and uncertainties related to the clinic's ability to use Antineoplastons A10 and AS2-1. Burzynski Clinic does not undertake to update any such forward-looking statements or to publicly announce developments or events relating to the matters described herein.

For Burzynski Clinic
Carolyn Powers, 713-335-5664
carolyn@burzynskiclinic.com


© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
React to this article
Latest news
Date Title
04:35p AMREST SE : RB 82/2016 Purchase of shares for the purposes related to the exercise of stock options plan
04:35p WESTMINSTER : New Contract Award – South Africa
04:35p EUROPEAN UNION : Ombudsman congratulates Dutch EU Presidency on transparency steps
04:35p DARTY : Form 8.3 -
04:35p DARTY : Form 8.3 -
04:35p PACIFIC HORIZON : Holding(s) in Company
04:35p 2012 ECONOMIC CENSUS CORE BUSINESS SERIES : Comparative Statistics
04:35p BARKERVILLE GOLD MINES : Intersects 30.98 G/T (0.90 Oz/T) Au Over 6.80 Metres In Cow Mountain Phase I Drilling — New Gold Extension Discovered
04:35p ENEA : published the CSR report for 2015
04:35p NET 1 UEPS TECHNOLOGIES : Net1 Announces Adoption of $50 Million 10b5-1 Plan
Latest news
Advertisement
Hot News 
Galena Biopharma Discontinues NeuVax™ (nelipepimut-S) Phase 3, PRESENT Interim Analysis based on Independent Data Monitoring Committee Recommendation
TESARO’s Niraparib Significantly Improved Progression-Free Survival for Patients With Ovarian Cancer in Both Cohorts of the Phase 3 NOVA Trial
DIAMOND RESORTS (DRII) ALERT : Johnson & Weaver, LLP Launches an Investigation into the Fairness of Price and Process in Proposed Sale of Diamond Resorts International, Inc.; Is $30.25 a Fair Price?
ECLIPSE RESOURCES CORPORATION : Prices Public Offering of Common Stock
BRAMMER : Share Price Halves On Profit Warning; May Scrap Interim Payout
Most Read News
06/28 VOLKSWAGEN : VW agrees to buy back diesel vehicles, fund clean air efforts
10:15a Oil edges up further as Brexit shock fades; U.S. drawdown seen
Most recommended articles
05:06aDJStocks Rise as Brexit Worries Ease
10:33aDJU.S. Government Bonds Hold Ground as Risk Appetite Increases
10:30aUNITED STATES : Crude Oil Inventories lower than estimates at -4.1M
10:29aDJBARCLAYS : Brexit Throws U.K. Banks' Strategy Into Turmoil
10:28a Adidas strikes new deal with Kanye West in U.S. market push